Replaces Prod. #: BML-CN264
Non-thiol-based nitric oxide (NO) donor. NOR-3 shows a variety of biological and pharmacological effects. Strong vasodilatory effects in rat aorta, rabbit aorta and dog coronary artery; potent inhibitory activities against antiplatelet aggregation and thrombus formation; effective aggregation inhibition of human platelet raising by ADP; cardioprotective effects in the ischemia/reperfusion system; antianginal effect.
Product Details
| Alternative Name: | FK409, (±)-(E)-4-Ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexeneamide |
| |
| Formula: | C8H13N3O4 |
| |
| MW: | 215.2 |
| |
| CAS: | 138472-01-2 |
| |
| Purity: | ≥97% (HPLC) |
| |
| Identity: | Identity determined by NMR. |
| |
| Appearance: | White to off-white crystalline solid. |
| |
| Solubility: | Soluble in DMSO (10mg/ml). |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Crystals are sensitive to moisture and become discolored on exposure to air. Solutions are stable for 1 month when stored at -20°C. Solvents should be purged with inert gas prior to addition of compound. |
| |
| Handling: | Protect from light and moisture. Packaged under inert gas. After reconstitution, prepare aliquots and store at -20°C. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Hypoxic and nitrosative stress conditions modulate expression of myoglobin genes in a carcinogenic hepatobiliary trematode, Clonorchis sinensis: S.H. Kim, et al.; PLoS Negl. Trop. Dis.
15, e0009811 (2021),
Abstract;
PKGI mediates the growth inhibitory effects of cGMP signaling in human breast cancer cells independent of β-catenin: P.F. Windham, et al.; Integr. Cancer Sci. Therap.
2, 185 (2015),
Application(s): Western Blot,
Full Text
Effect of nitric oxide release from NOR-3, on urea synthesis, viability and oxygen consumption of rat hepatocyte cultures: R. Chimenti, et al.; Physiol. Res.
56, 427 (2007),
Abstract;
Effects of pre- and post-ischemic treatments with FK409, a nitric oxide donor, on ischemia/reperfusion-induced renal injury and endothelin-1 production in rats: A. Nakajima, et al.; Biol. Pharm. Bull.
29, 577 (2006),
Abstract;
Full Text
Hydroxyimine NO-donors; FK409 and derivatives: K. Yoshida & Y. Kita; Curr. Top. Med. Chem.
5, 675 (2005),
Abstract;
Protective effect of nitric oxide on ischemia/reperfusion-induced renal injury and endothelin-1 overproduction: H. Kurata, et al.; Eur. J. Pharmacol.
517, 232 (2005),
Abstract;
Exposure of rat optic nerves to nitric oxide causes protein S-nitrosation and myelin decompaction: O.A. Bizzozero, et al.; Neurochem. Res.
29, 1675 (2004),
Abstract;
Kinetic characterization of the nitric oxide toxicity for PC12 cells: effect of half-life time of NO release: T. Yamamoto, et al.; Eur. J. Pharmacol.
397, 25 (2000),
Abstract;
Comparison of antiplatelet effects of two nitric oxide-donating agents, FR146801 and FK409: Y. Hirasawa, et al.; Thromb. Haemost.
79, 620 (1998),
Abstract;
Comparison of hemodynamic effects of nitric oxide (NO) donors with different NO-releasing properties in rats: Y. Kita, et al.; J. Cardiovasc. Pharmacol.
30, 223 (1997),
Abstract;
Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners: Y. Kita, et al.; J. Pharmacol. Exp. Ther.
276, 421 (1996),
Abstract;
FR144420, a novel, slow, nitric oxide-releasing agent: Y. Kita, et al.; Eur. J. Pharmacol.
275, 125 (1995),
Abstract;
Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409: Y. Kita, et al.; Eur. J. Pharmacol.
257, 123 (1994),
Abstract;
Characteristics of the vasorelaxing action of (3E)-4-ethyl-2- hydroximino-5-nitro-3-hexamide FK409, a new vasodilator isolated from microbial sources, in isolated rabbit arteries: S. Shibata, et al.; J. Cardiovasc. Pharmacol.
17, 508 (1991),
Abstract;
Comparison of the effects of the novel vasodilator FK409 with those of nitroglycerin in isolated coronary artery of the dog: H. Yamada, et al.; Br. J. Pharmacol.
103, 1713 (1991),
Abstract;
FK409, a novel vasodilator isolated from the acid-treated fermentation broth of Streptomyces griseosporeus. I. Taxonomy, fermentation, isolation, and physico-chemical and biological characteristics: N. Hino, et al.; J. Antibiot. (Tokyo)
42, 1578 (1989),
Abstract;
